Certara, Inc. Earnings Recaps
Q2 2026
Aug 6, 2026
Shares declined 2.1% following Certara’s Q2 report as investors appeared unimpressed by modest revenue growth, persistent service revenue weakness, and cautious full-year guidance despite ongoing transformation efforts.
Key takeaways
- Revenue grew 1% in Q2, with software up 4% but services down 3%, reflecting ongoing challenges in the services segment.
- Trailing 12-month software bookings rose 7% (excluding Chemaxon), showing some momentum improvement from prior periods.
- Services bookings remained sluggish with a 1.07 book-to-bill ratio, partly impacted by divestiture of regulatory and medical writing businesses.
- The company reaffirmed full-year revenue growth guidance of 0% to 4%, signaling a cautious outlook.
- Cost reduction efforts, including a 5% workforce reduction, are expected to generate $13 million in run-rate savings to support innovation investments.
Q1 2026
May 12, 2026
Shares plunged 18.7% on signs of deceleration and a cautious outlook that failed to convince investors the company can deliver durable growth despite management’s long-term ambitions.
Key takeaways
- First quarter performance was described as "in line" with expectations but fell short of reflecting Certara’s potential, highlighting underlying growth concerns.
- CEO emphasized restructuring and operational rigor to drive long-term growth, signaling current execution challenges.
- The company highlighted strong regulatory foothold and scientific leadership, but these strengths alone have not translated into near-term market enthusiasm.
- Management flagged expansion into AI-driven drug discovery as a key growth driver, yet investors appear unconvinced by the timeline or impact.
- No specific financial metrics or margin commentary were provided to offset concerns, contributing to the negative market reaction.